Albireo to Report Q4 and Year-End 2020 Financial Results on February 25

Rhea-AI Summary

Albireo Pharma (Nasdaq: ALBO) will hold a conference call on February 25, 2021, at 10:00 a.m. ET, to share a business update and review financial results for Q4 and the year ended December 31, 2020. The company, focused on developing novel bile acid modulators for rare pediatric liver diseases, will discuss its lead candidate, odevixibat, undergoing Phase 3 pivotal trials.

For participation, call 877-407-0792 (domestic) or 201-689-8263 (international), using access code 13715566. A webcast will also be available on their website.

Positive

• Conference call scheduled to discuss business update and financial results.
• Lead product candidate, odevixibat, in Phase 3 trials for rare pediatric liver diseases.

Negative

• None.

Conference call and webcast to be held at 10:00 a.m. ET

BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on February 25, 2021, to provide a business update and review the company’s financial results for the fourth quarter and year ended December 31, 2020.

To access the live conference call by phone, please dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13715566. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website, https://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event.

About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lisa Rivero, 617-947-0899, lisa.rivero@syneoshealth.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

FAQ

What is the date of Albireo Pharma's conference call?

Albireo Pharma's conference call is scheduled for February 25, 2021.

What will be discussed in the Albireo Pharma conference call?

The conference call will cover a business update and the financial results for the fourth quarter and year ended December 31, 2020.

How can I access the Albireo Pharma conference call?

You can access the call by dialing 877-407-0792 (domestic) or 201-689-8263 (international) and providing access code 13715566, or by visiting their website for the live audio webcast.

What is the focus of Albireo Pharma's product development?

Albireo Pharma focuses on novel bile acid modulators to treat rare pediatric and adult liver diseases.

What are the clinical developments of Albireo's lead candidate, odevixibat?

Odevixibat is being developed for rare pediatric cholestatic liver diseases and is currently in Phase 3 pivotal trials.